Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Paying user area
Try for free
Abbott Laboratories pages available for free this week:
- Common-Size Income Statement
- Common-Size Balance Sheet: Assets
- Analysis of Long-term (Investment) Activity Ratios
- Analysis of Reportable Segments
- Common Stock Valuation Ratios
- Enterprise Value to FCFF (EV/FCFF)
- Capital Asset Pricing Model (CAPM)
- Debt to Equity since 2005
- Price to Book Value (P/BV) since 2005
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Abbott Laboratories for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Profitability Ratios (Summary)
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
- Gross Profit Margin
- The gross profit margin showed a generally stable trend from March 2021 to June 2025, fluctuating within a narrow range around 50% to 53.5%. The margin peaked in the fourth quarter of 2022 at approximately 53.54%, followed by a slight decline and subsequent stabilization near 51.5% to 51.9% towards mid-2025. This indicates consistent control over production costs relative to revenues throughout the period.
- Operating Profit Margin
- Operating profit margin exhibited an overall declining trend after reaching a high point of 22.42% in the third quarter of 2022. Following this peak, the margin steadily decreased to a low of around 15.02% by the fourth quarter of 2023. Subsequent quarters show a modest recovery, climbing gradually to approximately 17.43% by the second quarter of 2025. This pattern suggests increasing operating expenses or shifts in business operations affecting operating profitability.
- Net Profit Margin
- The net profit margin followed a pattern similar to the operating profit margin, initially increasing to a peak of 18.78% in the third quarter of 2022 before declining to roughly 12.83% in the third quarter of 2023. Notably, from the fourth quarter of 2024 onward, there is a sharp increase to approximately 32%, which marks a significant improvement in net profitability. This sharp rise may be attributable to extraordinary gains, cost reductions, or tax impacts in that period.
- Return on Equity (ROE)
- Return on equity increased steadily from 13.71% in the first quarter of 2021 to a peak of 23.44% in the third quarter of 2022. This was followed by a decline to levels near 13.77% by the fourth quarter of 2023. A strong upward movement is observed again after the fourth quarter of 2024, reaching approximately 28% by mid-2025. The fluctuations in ROE reflect changes in net income relative to shareholders’ equity, possibly due to shifts in profitability or capital structure.
- Return on Assets (ROA)
- Return on assets increased from 6.2% in the first quarter of 2021 to a high of 11.53% in the third quarter of 2022. Following this, ROA declined to under 7.2% by the fourth quarter of 2023. From late 2024 onward, a notable increase is apparent, with ROA reaching around 16.6% by mid-2025. This trend suggests improved asset utilization and efficiency in generating profit during the latter stages of the series.
Return on Sales
Return on Investment
Gross Profit Margin
Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
Gross profit | |||||||||||||||||||||||||||||
Net sales | |||||||||||||||||||||||||||||
Profitability Ratio | |||||||||||||||||||||||||||||
Gross profit margin1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
Gross Profit Margin, Competitors2 | |||||||||||||||||||||||||||||
Elevance Health Inc. | |||||||||||||||||||||||||||||
Intuitive Surgical Inc. | |||||||||||||||||||||||||||||
Medtronic PLC | |||||||||||||||||||||||||||||
UnitedHealth Group Inc. |
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
Gross profit margin = 100
× (Gross profitQ2 2025
+ Gross profitQ1 2025
+ Gross profitQ4 2024
+ Gross profitQ3 2024)
÷ (Net salesQ2 2025
+ Net salesQ1 2025
+ Net salesQ4 2024
+ Net salesQ3 2024)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
- Gross Profit
- The gross profit exhibits notable fluctuations over the periods observed. Initially, there is a decline from 3,884 million USD at March 31, 2020, to 3,512 million USD by June 30, 2020. Subsequently, it rises sharply to reach a peak of 6,188 million USD at December 31, 2021. After this peak, a gradual downward trend is evident, with values decreasing to 4,925 million USD by March 31, 2023. Thereafter, gross profit stabilizes, showing modest increases and decreases, ultimately reaching 5,868 million USD at June 30, 2025. Overall, gross profit demonstrates a cyclical pattern with periods of growth interrupted by declines.
- Net Sales
- Net sales present a general upward trajectory across the timeline. Starting from 7,726 million USD at March 31, 2020, net sales experience an increase, peaking at 11,468 million USD by December 31, 2021. Following this peak, there is a slight decrease by March 31, 2023, falling to 9,747 million USD, indicative of a short-term contraction. However, the trend recovers thereafter, with net sales climbing steadily to 11,142 million USD by June 30, 2025. This pattern suggests sustained growth with intermittent periods of softness.
- Gross Profit Margin
- The gross profit margin remains relatively stable throughout the reporting periods, operating within a narrow band slightly above 50%. Beginning at 50.49% in March 31, 2020, the margin experiences a gradual increase, achieving peaks exceeding 52% between December 31, 2020, and March 31, 2022. Subsequently, it oscillates within the range of approximately 50% to 52%, ending at 51.9% in June 30, 2025. The stability of the margin indicates consistent pricing power and cost control despite variations in gross profit and net sales figures.
Operating Profit Margin
Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
Operating earnings | |||||||||||||||||||||||||||||
Net sales | |||||||||||||||||||||||||||||
Profitability Ratio | |||||||||||||||||||||||||||||
Operating profit margin1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
Operating Profit Margin, Competitors2 | |||||||||||||||||||||||||||||
Elevance Health Inc. | |||||||||||||||||||||||||||||
Intuitive Surgical Inc. | |||||||||||||||||||||||||||||
Medtronic PLC | |||||||||||||||||||||||||||||
UnitedHealth Group Inc. |
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
Operating profit margin = 100
× (Operating earningsQ2 2025
+ Operating earningsQ1 2025
+ Operating earningsQ4 2024
+ Operating earningsQ3 2024)
÷ (Net salesQ2 2025
+ Net salesQ1 2025
+ Net salesQ4 2024
+ Net salesQ3 2024)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The data reveals several noteworthy trends in key financial metrics over the examined period. Operating earnings exhibit considerable volatility, with values fluctuating significantly from quarter to quarter. Initially, there is a sharp increase from March 2020 to December 2020, peaking at 2,432 million US dollars. However, in the subsequent quarters, operating earnings show a declining pattern followed by intermittent recoveries, without a clear long-term upward or downward trend. The most recent quarters indicate some recovery, with an upward movement noted towards the end of the series.
Net sales show a general upward trend despite some fluctuations. Starting at 7,726 million US dollars in March 2020, net sales increase steadily with minor dips, reaching over 11,000 million US dollars by the end of the latest period. This steady growth in net sales suggests a strengthening revenue base or expanding market presence despite short-term variability.
Operating profit margin, available solely from the fourth quarter of 2020, indicates a generally stable and slightly improving profitability ratio. Margins start around 15.48% and increase gradually, peaking at values above 22% during 2022, before settling around 16-17% in the most recent periods. This stability in operating profit margin amidst fluctuations in operating earnings and net sales points to effective cost control or operational efficiency initiatives over the medium term.
- Operating Earnings
- Display high volatility with significant quarter-to-quarter fluctuations; an early peak at the end of 2020 followed by periods of decline and partial recovery toward the end of the dataset.
- Net Sales
- Generally trend upwards, indicating growth in revenue with minor fluctuations; consistent expansion evident over several years.
- Operating Profit Margin
- Maintains relative stability within a moderate range; peaks above 20% in 2022 before normalizing to mid-to-high teens in the latest quarters, reflecting steady operational efficiency.
In summary, the financial data depicts a business with expanding sales revenue and relatively stable profitability ratios, despite operating earnings experiencing variability. The firm appears to sustain operational efficiency through periods of earnings fluctuation, supporting overall profitability continuity.
Net Profit Margin
Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
Net earnings | |||||||||||||||||||||||||||||
Net sales | |||||||||||||||||||||||||||||
Profitability Ratio | |||||||||||||||||||||||||||||
Net profit margin1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
Net Profit Margin, Competitors2 | |||||||||||||||||||||||||||||
Elevance Health Inc. | |||||||||||||||||||||||||||||
Intuitive Surgical Inc. | |||||||||||||||||||||||||||||
Medtronic PLC | |||||||||||||||||||||||||||||
UnitedHealth Group Inc. |
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
Net profit margin = 100
× (Net earningsQ2 2025
+ Net earningsQ1 2025
+ Net earningsQ4 2024
+ Net earningsQ3 2024)
÷ (Net salesQ2 2025
+ Net salesQ1 2025
+ Net salesQ4 2024
+ Net salesQ3 2024)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The financial data exhibits several noteworthy trends across net earnings, net sales, and net profit margin over the analyzed quarterly periods.
- Net Earnings
- Net earnings show significant variability over time, with several pronounced peaks and troughs. Initial quarters reflect moderate earnings with a marked increase by December 2020, reaching 2162 million USD. Following that, a downward trend is observed through mid-2021, then rising again through late 2021 to early 2022. Subsequent quarters display a decline through late 2022 but gradually recover through 2023 and early 2024, before experiencing a substantial surge reaching 9229 million USD by March 2025. This spike suggests either an extraordinary event or seasonal/one-off factors impacting profitability.
- Net Sales
- Net sales generally demonstrate a more stable and upward trajectory compared to net earnings, indicating steady revenue generation. Sales start at 7726 million USD in March 2020 and generally trend upward, peaking near 11468 million USD in December 2021. This is followed by slight fluctuations but remains relatively consistent around 10,000 to 11,000 million USD in subsequent years. Despite minor dips, the overall sales trend is positive with recurrent seasonal variability.
- Net Profit Margin
- The net profit margin shows a gradual increase from early reported periods, starting around 13% in March 2021 and climbing close to 18% by September 2022. This suggests improving efficiency or profitability relative to sales during this timeframe. However, there is a downward adjustment after this peak, with margins settling around 13-14% through 2023 and early 2024. Notably, margins then exhibit an abrupt increase above 31% in the last three reported quarters, coinciding with the sharp rise in net earnings. This anomalous surge in profit margin implies enhanced profitability, potentially from non-recurring gains or cost management improvements that are significantly impacting earnings relative to sales.
In summary, net sales exhibit consistent growth with moderate volatility, net earnings experience substantial fluctuations with an extraordinary surge toward the end of the period, and net profit margins generally improve over time but show exceptional spikes in the latest quarters. These patterns suggest periods of operational strength combined with episodic earnings volatility, highlighting areas for further investigation into the underlying drivers of profitability.
Return on Equity (ROE)
Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
Net earnings | |||||||||||||||||||||||||||||
Total Abbott shareholders’ investment | |||||||||||||||||||||||||||||
Profitability Ratio | |||||||||||||||||||||||||||||
ROE1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
ROE, Competitors2 | |||||||||||||||||||||||||||||
Elevance Health Inc. | |||||||||||||||||||||||||||||
Intuitive Surgical Inc. | |||||||||||||||||||||||||||||
Medtronic PLC | |||||||||||||||||||||||||||||
UnitedHealth Group Inc. |
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
ROE = 100
× (Net earningsQ2 2025
+ Net earningsQ1 2025
+ Net earningsQ4 2024
+ Net earningsQ3 2024)
÷ Total Abbott shareholders’ investment
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
The analysis of the quarterly financial performance indicates several notable trends in net earnings, shareholders' investment, and return on equity (ROE) over the examined periods.
- Net Earnings
- The net earnings exhibit considerable volatility across the quarters. Starting with moderate levels around US$ 500-600 million in early 2020, there is a marked increase reaching peaks above US$ 2 billion in the latter part of 2020 and into early 2021. Subsequent quarters show fluctuations with a general downward trend during late 2022 and early 2023, followed by a gradual recovery towards the end of 2023 and into 2024. Notably, the first quarter of 2025 records an exceptionally high net earning of US$ 9,229 million, which is a significant spike relative to preceding quarters.
- Total Shareholders’ Investment
- This metric shows a steady upward trajectory throughout the entire timeline. Beginning at approximately US$ 30.2 billion in early 2020, the total shareholders' investment consistently grows, reflecting continued capital influx or retained earnings accumulation. By the first quarter of 2025, the value reaches about US$ 50.5 billion. The steady growth pattern indicates ongoing confidence from investors and effective capital management.
- Return on Equity (ROE)
- The ROE data, available for most periods starting late 2020, illustrates a generally strong and stable profitability relative to shareholders' equity. Initial values around 13.7% climb to a peak of approximately 23.4% in late 2021, suggesting improved efficiency or profitability during that phase. Following this peak, ROE declines gradually to levels near 13.8% through 2023, after which it stabilizes in the 14–15% range. The first quarter of 2025 shows a significant jump in ROE to over 27%, consistent with the sharp increase in net earnings in the same period.
In summary, the company demonstrates a robust ability to increase shareholders' investment steadily over time, accompanied by fluctuating but generally strong net earnings and profitability. The spike in net earnings and ROE in early 2025 may warrant further investigation to understand underlying causes and to assess sustainability. The overall financial health appears solid, with effective use of equity generating consistent returns, despite earnings volatility in some quarters.
Return on Assets (ROA)
Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
Net earnings | |||||||||||||||||||||||||||||
Total assets | |||||||||||||||||||||||||||||
Profitability Ratio | |||||||||||||||||||||||||||||
ROA1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
ROA, Competitors2 | |||||||||||||||||||||||||||||
Elevance Health Inc. | |||||||||||||||||||||||||||||
Intuitive Surgical Inc. | |||||||||||||||||||||||||||||
Medtronic PLC | |||||||||||||||||||||||||||||
UnitedHealth Group Inc. |
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
ROA = 100
× (Net earningsQ2 2025
+ Net earningsQ1 2025
+ Net earningsQ4 2024
+ Net earningsQ3 2024)
÷ Total assets
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
The analyzed financial data reveals several notable trends concerning net earnings, total assets, and return on assets (ROA) over multiple quarterly periods.
- Net earnings
- Net earnings exhibit considerable volatility throughout the observed timeframe. Initial quarters show moderate earnings in the range of approximately 500 to 2,000 million US dollars, with a peak in the December 2024 quarter reaching 9,229 million US dollars, significantly above other periods. Following this peak, earnings fluctuate again, with some quarters dropping below the 1,500 million mark. This suggests episodic spikes in profitability potentially driven by non-recurring events or one-time gains in certain periods.
- Total assets
- Total assets demonstrate a generally stable to slightly increasing trend over time. The values fluctuate within a relatively narrow range from about 66,777 million US dollars in the early quarters to exceeding 83,000 million US dollars by the end of the timeline. The steady asset base indicates consistent capital investment and asset retention, with no dramatic contractions or expansions visible.
- Return on assets (ROA)
- The ROA metric shows a clear upward trajectory from the beginning of available data, rising from approximately 6.2% to surpassing 10% within several quarters. Subsequently, ROA stabilizes around the 7% to 8% range for a prolonged period, before markedly jumping to above 16% in the final three quarters presented. This marked increase in ROA coincides with the significant spike in net earnings, reflecting enhanced efficiency in generating profits from asset investments during these later periods.
Overall, the data implies that the company maintained a solid asset base while experiencing variable earnings performance. The substantial surge in net earnings and accompanying ROA improvement toward the end of the reporting period stands out as a key development, meriting further investigation into the factors driving this elevated profitability.